the CA arm and three in the C arm had their planned treatment discontinued owing to progressive disease (n = 3), amifostine side-effects (hypotension, sneezing and sickness, n = 4), and carboplatin-induced thrombocytopenia (n = 1). Bone marrow and renal function at study entry and after the first course of carboplatin before randomisation were similar in both treatment arms. Twenty courses of carboplatin + amifostine have been compared with 25 courses of carboplatin alone. Although there was no statistically significant difference with respect to haematological values comparing both arms, the median time to platelet recovery (>100 x 109 1-l) (13.5 days vs 21 days; P = 0.04) and the need for hospitalisation for i.v. antibiotic and other supportive treatment tended to be reduced in the CA arm (0/20 vs 6/25 patient courses; P = 0.06). Response rates and median survival (14 vs 9 months) were no different, excluding tumour protection activity by amifostine. These results with a small number of patients suggest that amifostine given with carboplatin may reduce the duration of thrombocytopenia and hospitalisation.
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Keywords: carboplatin; non-small-cell lung cancer; amifostine; WR-2721; thrombocytopenia; infection Amifostine (Ethyol), previously referred to as WR-2721, is an organic thiophosphate which was developed by the US army during the cold war as a radioprotective agent (McCulloch et al., 1991; Capizzi et al., 1993) . In animal models, it also protects normal tissue against the toxicity of cytotoxic agents such as platinum and alkylating compounds (Yuhas et al., 1980; Patchen et al., 1992; Treskes et al., 1994; van der Vijgh et al., 1994) . Amifostine is a prodrug that is dephosphorylated to its active metabolite, a free thiol, by alkaline phosphatase at the tissue site. Coupled with the fact that normal tissue concentrates the free thiol metabolite, it is immediately available to bind and detoxify alkylating and platinum agents (Treskes et al., 1991; van der Vijgh et al., 1994) . The administration of amifostine together with chemotherapy suggests that it might have value in protecting patients from myelosuppression Glick et al., 1992; Budd et al., 1993; Capizzi, 1994; Poplin et al., 1994) and, in the case of cisplatinum-containing schedules, from neurotoxicity and nephrotoxicity (Mollman et al., 1988; Glick et al., 1992) .
Carboplatin as a single agent therapy has been shown to have activity in non-small-cell lung cancer (NSCLC) with response rates from 8% to 20% in four trials testing carboplatin 400 mg m-2 as a single dose or fractionated over 3 days (Bonomi, 1991) . In a recent phase I dose-escalating study in patients with lung tumour, carboplatin was administered in a dosage of 800, 1200 and 1600 mg m-2 (Smith, 1992 min-' and if the following haematological criteria were met: WBC > 3 x 109 1-l, platelet >100 x I0 I-'. Platelet and/or red blood cell transfusions were given in the case of thrombocytopenia (<20 x 109 1') and/or anaemia (<95 g I`).
Drugs, which would have affected bone marrow function and/or blood cell count (e.g. steroids) and blood pressure (e.g. phenothiazine), were not prescribed.
Response assessment Pretreatment evaluation included a medical history, physical examination, full blood count, biochemical profile, chest radiograph, computerised tomography (CT) scan and any other diagnostic procedure appropriate to assess the extent of the disease. Blood counts were performed weekly. Physical examination and biochemical profile were carried out according to WHO criteria every two courses (World Health Organization, 1979) .
Toxicity
Side-effects were reported according to the standard WHO criteria. If patients developed fever in association with neutropenia and/or platelet count <20 x 109 1-l (in the case of bleeding <50 x 109 1-) the subsequent carboplatin dose could be reduced by 25%. All patients treated with amifostine had their blood pressure measured immediately before and every 5 min during the amifostine infusion until 5 min after the infusion was completed. If the systolic blood pressure dropped more than 20% from the baseline value or if the patient developed symptoms related to decreased cerebral perfusion, the infusion of amifostine was interrupted. As soon as the patient had recovered (absence of symptoms, blood pressure above the threshold value within S min of stopping the infusion), the amifostine treatment was restarted. In the case of prolonged blood pressure drop, all subsequent doses of amifostine were reduced by 20%.
Statistical analysis Log-rank, Wilcoxon rank sum and Fisher's exact tests were used for comparing the haematological values, the occurrence of infections, the need for transfusions and antibiotics and times to platelet, WBC and neutrophil recovery within each treatment arm and between the two arms. The worst nadir blood counts taken from the weekly counts were used for analysis. A Kaplan-Meier analysis was used to assess the median time to platelet/blood transfusion for each treatment arm and survival.
Results

Patient characteristics
A total of 21 patients were enrolled in this randomised study. Their clinical characteristics are summarised in Table I . One patient declined the amifostine treatment after randomisation (CA arm) and was therefore followed up only for response and survival. Major prognostic factors were well balanced between both arms and measurements of the renal function (serum creatinine and creatinine clearance) as well as the blood cell counts revealed no statistically significant difference before randomisation.
Treatment and toxicity (Table II) Five of the ten patients in the carboplatin/amifostine arm (CA arm) [20] [21] [22] [23] [24] [25] [26] in the CA arm had the carboplatin dose reduced or discontinued owing to pancytopenia. Although there was no statistically significant difference in the infection incidence comparing both treatment groups (10/ 25 and 3/20 for C and CA respectively), patients in the C arm tended to be hospitalised more frequently mainly for i.v. antibiotics and other supportive treatment (6/25 vs 0/20 patient courses, P = 0.06).
Tumour response and survival The response rate was evaluable in 19 patients (in two patients, one in each arm, tumour size was not assessable owing to lung atelectasis); seven patients had a partial response, five in the CA arm (5/10), and two in the C arm (2/9). Four patients in the CA arm and one patient in the C arm who responded had limited disease. The median survival was 14 months and 9 months in the CA and C groups respectively.
Discussion
Amifostine is a thiol compound that is thought to protect normal bone marrow against the toxic effects of chemotherapy while not diminishing the antineoplastic efficacy of the cytotoxic agent (Gandara et al., 1990 (Gandara et al., , 1991 McCulloch et al., 1991; Schuchter et al., 1992; Capizzi et al., 1993 Capizzi et al., , 1994 Treskes et al., 1993) . Recently published studies have shown a lessening of pancytopenia and/or a shortened time to recovery for neutrophils and platelets if amifostine was given with chemotherapy Glick et al., 1992 Glick et al., , 1994 Budd et al., 1993; Poplin et al., 1994) . These therapies included agents such as cyclophosphamide Glick et al., 1994) , cisplatinum (Glover et al., 1987; Mollman et al., 1988; Glick et al., 1992 Glick et al., , 1994 Schiller et al., 1994) , mitomycin (Poplin et al., 1994) and vinblastine (Poplin et al., 1994) . In addition, a reduction in infections requiring antibiotics and days in hospital has been reported in a large randomised phase III study of patients with ovarian cancer treated with cisplatinum and cyclophosphamide (Glick et al., 1994) . A possible protection of amifostine with carboplatin has been recently suggested in a phase I investigation (Budd et al., 1993) .
Pharmacokinetic studies in phase I clinical trials revealed that amifostine is cleared from the plasma within 6min of the completion of a 15 min infusion (half-life time T 1/2: a 0.9 min and 9 min) (Shaw et al., 1986) . These pharmacokinetic data, therefore, are important in planning clinical protection trials and support the rationale for repeated amifostine administration particularly when used with carboplatin for which the half-life is relatively long (a; 30-60min and ,B; 450-1200min) (Van Echo et al., 1989) .
In the present randomised phase II study, we investigated the haematological toxicity after monotherapy with carboplatin for inoperable NSCLC. The predominant haematolog- ical toxicity associated with carboplatin is thrombocytopenia (Canetta et al., 1985) . Although the severity of thrombocytopenia was not influenced by amifostine, the time to recovery appeared to be shortened compared with patients treated with carboplatin alone (P = 0.04) ( Table III) . The need for hospitalisation for i.v. antibiotic and other supportive treatment tended to be less in the amifostine group (P = 0.06). Although the neutrophil nadir count and time to recovery were similar, perhaps because of the analysis having been performed on the worst counts rather than the median values of the weekly counts, no other statistically significant differences were seen and the need for transfusions were similar in both patient arms. The results could also be due to the cumulative nature of carboplatin's haematological toxicity and a possible 'carry over' effect from the first course of carboplatin.
Although renal and bone marrow function were well balanced between both groups, the carboplatin AUC as back calculated from the dose given and creatinine clearances (Calvert et al., 1989) was significantly greater (7%) in the CA arm on courses 3-4. This difference is due, at least to some extent, to dose reduction of carboplatin in one patient in the C arm. This finding strengthens the results with respect to amifostine effect on platelet recovery duration and incidence of severe infection.
Amifostine led to important side-effects such as hypotension, malaise, retching and sneezing at a dose level of 910 mg m2 t.i.d. Subsequent doses, therefore, were reduced by 25% to 683 mg m-2 t.i.d. At this dose level, amifostine was well tolerated and, as in other studies, nausea, vomiting, flushing, episodic sneezing, dizziness and hypotension were mild to moderate in intensity. No hypocalcaemia observed previously (Wadler et al., 1993; O'Rourke et al., 1994) was noticed and there was no evidence of cumulative toxicity from the three daily doses of amifostine.
Studies in animal models suggest an increased response rate when amifostine is administered. In mice with ovarian carcinoma xenografts (Treskes et al., 1994) amifostine administered before carboplatin had a potentiating effect on tumour growth inhibition. In a randomised trial in patients with ovarian cancer (Glick et al., 1992) complete responses and survival with a median follow-up of 40 months were similar. In the present study the number of patients is too small to allow any conclusion on response. Nevertheless, the response and survival data like the study performed in ovarian cancer (Glick et al., 1992) argues against any tumour protection by amifostine.
Taken together, no activity of amifostine on the blood cell nadir, transfusions, time to recovery of neutrophils and haemoglobin could be observed in the present study. Therefore, it was considered unreasonable to recruit additional patients onto this study. However, amifostine given with carboplatin appears to shorten the duration of carboplatin-induced thrombocytopenia and tends to reduce hospitalisation with fewer infections necessitating the use of i.v. antibiotics and less supportive care. Further randomised studies, in which carboplatin dosage is based on the AUC calculation, and in which amifostine (at a dose level of 683 mg m-2 t.i.d.) is given with the first chemotherapy course in order to avoid a possible cumulative carboplatin toxic effect, will be needed to confirm these results.
